BMY Bristol-Myers Squibb
- 44.550
- -0.160-0.36%
- 44.550
- 0.0000.00%
Bristol-Myers Squibb News
Tudor Investment's Top Buys and Sells in Q1
UPDATE 1-US FDA Approves Expanded Use of Bristol's Cancer Cell Therapy
FDA Grants Accelerated Approval To Bristol Myers Squibb's Lisocabtagene Maraleucel For Follicular Lymphoma
FDA Grants Accelerated Approval To Bristol Myers Squibb's Lisocabtagene Maraleucel For Follicular Lymphoma
Bristol Myers Squibb Company (BMY) Is Attracting Investor Attention: Here Is What You Should Know
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
One Stock Is Dragging Down the S&P 500's Earnings Growth
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Bristol Myers BMY recently announced that a late-stage study, seeking to expand the label of its cancer combination drug, Opdivo (nivolumab) and Yervoy (ipilimumab), failed to meet the primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).
Bristol-Meyers Squibb Sunk S&P 500 This Earnings Season: FactSet
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
These Stocks Are Moving the Most Today: Tesla, Arm, Bristol Myers, GameStop, and More -- Barrons.com
By Joe Woelfel Stock futures were pointing higher Monday as investors awaited key U.S. inflation data later in the week and earnings reports from major retailers. These stocks were poised to make mo
Bristol Myers' Opdivo Fails in Phase 3 Lung Cancer Study
Bristol Myers (NYSE:BMY) said that a Phase 3 study of Opdivo with Yervoy with in the treatment of advanced lung cancer failed to meet its primary endpoint of progression-free survival.
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint
Bristol-Myers Squibb (BMY) said late Friday a phase 3 trial assessing Opdivo to potentially treat non-small cell lung cancer failed to reach its primary endpoint of progression-free survival. The tria
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
By Ben Glickman Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer treatments failed to meet its primary endpoint. The company's trial was evaluating the cancer-dr
Bristol Myers Squibb Shares Update On Phase 3 CheckMate -73L Trial; Says Trial Did Not Meet Its Primary Endpoint Of Progression-Free Survival In Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-sm
Bristol Myers Squibb Shares Are Trading Lower After the Company's Phase 3 CheckMate -73L Trial Did Not Meet Its Primary Endpoint.
Bristol Myers Squibb Shares Are Trading Lower After the Company's Phase 3 CheckMate -73L Trial Did Not Meet Its Primary Endpoint.
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Friday, Aethlon Medical Inc (NASDAQ:AEMD) released results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles (EVs) from plasma. Extracellular vesicles contribute to
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high
Drugmakers in Medicare Price Negotiations Spent Less on Research Than on Shareholder Payments, Marketing and Overhead: Report
Bristol-Myers Squibb Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution
Analysis
Price Target
No Data
